PBS updates

Remsima SC (Infliximab)

infliximab 120 mg/mL injection, 1 mL syringe · INJECTION · PBS code 12555T

AUTHORITY_REQUIRED

What it costs

AU$332.8 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2021-07-01.
  • • Repeats: 0.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe active rheumatoid arthritis


Balance of supply for Initial treatment - subcutaneous form


Must be treated by a rheumatologist; or

Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND

Patient must have received insufficient therapy with this drug for this condition under the Initial treatment with subcutaneous form restriction to complete 22 weeks initial treatment (intravenous and subcutaneous inclusive); AND

The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND

The treatment must provide no more than the balance of up to 22 weeks treatment available under the Initial treatment - subcutaneous form; AND

Patient must be at least 18 years of age.

Sponsor: Celltrion Healthcare Australia Pty Ltd ABN 66 625 407 105

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.